GENE EXPRESSION PROFILING OF UNKNOWN PRIMARY CANCERS

描述：(申请人描述) 原发部位不明的癌症是诊断和治疗的两难境地 肿瘤学。来自DNA微阵列技术的基因表达信息 癌症的特征导致了一种假设，即有几组诊断集 可解决未知原发癌症(UPC)起源的基因 高度自信。这个项目的目的是测试这一点 假设：通过对UPC病例的回顾和前瞻性分析 来自斯坦福医学中心和萨拉·坎农癌症中心，在 快速进化的特定位点基因簇数据库的背景 表情。具体目标是：(1)定义基因表达谱 已知的人类癌症。我们现在有关于以下方面的大量信息 淋巴瘤、白血病和乳腺癌、前列腺癌、肺癌、卵巢癌和 肝脏。我们的肿瘤库和正在进行的样本中将积累更多的肿瘤 收购对象包括肉瘤、生殖细胞癌、黑色素瘤、间皮瘤、 以及结肠癌、胃癌、胰腺癌、膀胱癌和肾癌。(2) 确定每一个基因表达的诊断性簇 高于肿瘤类型。我们预计数百个基因可能会分化 从这些已知的肿瘤中选出一个。(3)获得、基因表达 未知原发癌症标本的概况分析和诊断分类。 这一目标将涉及与世界领先的中心密切合作 对于未知原发癌症的临床评估，Sarah Cannon 纳什维尔的癌症中心。(4)一组组织特异性的评价 用于UPC标本诊断的抗血清。这一目标将利用 追溯性存档样本以及预期获得的样本 从这个项目中。(5)鉴定特定或聚集的基因表达 与已知的预后因素、治疗反应和存活率有关 UPC患者的比例。

DESCRIPTION: (Applicant's Description) Cancers of unknown primary site are a diagnostic and therapeutic dilemma in oncology. Information from DNA micro array technologies on the gene expression profile of cancers has led to the hypothesis that there are diagnostic sets of genes which can resolve the origin of unknown primary cancers (UPC) with a high degree of confidence. The purpose of this project is to test this hypothesis, by both retrospective and prospective analysis of cases of UPC from Stanford Medical Center and the Sarah Cannon Cancer Center, in the context of a rapidly evolving database of site-specific clusters of gene expression. Specific Aims are: (1) Definition of the gene expression profile of known human cancers. We now have extensive information on the profiles of lymphomas, leukemia, and carcinomas of the breast, prostate, lung, ovary, and liver. Additional tumors to be accrued from our tumor bank and ongoing sample acquisitions include sarcomas, germ cell cancers, melanomas, mesotheliomas, and carcinomas of the colon, stomach, pancreas, bladder, and kidney. (2) Determination of the diagnostic cluster of gene expression for each of the above tumor types. We anticipate that several hundred genes may differentiate one from the others of these known tumors. (3) Acquisition, gene expression profiling, and diagnostic classification of unknown primary cancer specimens. This aim will involve a close collaboration with the world's leading center for the clinical evaluation of unknown primary cancers, the Sarah Cannon Cancer Center in Nashville. (4) Evaluation of a panel of histospecific antisera for diagnostic utility with UPC specimens. This aim will utilize retrospective archived specimens as well as prospectively acquired samples from this project. (5) Identification of specific or clustered gene expression associated with known prognostic factors, response to therapies, and survival of patients with UPC.